StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a research note published on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Marinus Pharmaceuticals Trading Down 0.2 %
NASDAQ MRNS opened at $0.55 on Tuesday. The company has a fifty day simple moving average of $0.55 and a 200 day simple moving average of $0.76. The company has a market cap of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 1 year low of $0.22 and a 1 year high of $9.41.
Institutional Trading of Marinus Pharmaceuticals
Several large investors have recently modified their holdings of the company. World Investment Advisors LLC bought a new stake in Marinus Pharmaceuticals in the 3rd quarter valued at $104,000. Virtu Financial LLC bought a new stake in Marinus Pharmaceuticals in the 4th quarter valued at $36,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in Marinus Pharmaceuticals in the 4th quarter valued at $54,000. JPMorgan Chase & Co. boosted its holdings in Marinus Pharmaceuticals by 1,968.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 126,752 shares during the period. Finally, Deltec Asset Management LLC bought a new stake in Marinus Pharmaceuticals in the 4th quarter valued at $107,000. 98.80% of the stock is owned by institutional investors.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
See Also
- Five stocks we like better than Marinus Pharmaceuticals
- What is Forex and How Does it Work?
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- What Are Growth Stocks and Investing in Them
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- Financial Services Stocks Investing
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
